PRESS RELEASE ARCHIVE
08. May 2020
Bachem and Jitsubo enter into exclusive Licensing AgreementBubendorf/Basel, Switzerland and Yokohama, Japan, May 8, 2020 – Bachem (SIX: BANB) and Jitsubo CO.,… more |
13. Mar 2020
Fiscal Year 2019 - Record year points to increasing growth dynamicsSales pass 300-million mark for the first time at 313.7 million CHFEBIT margin rises to 19.9%,… more |
03. Mar 2020
Changes on the Board of Directors of Bachem Holding AGBubendorf/Basel, Switzerland, March 3, 2020 – The Bachem Group (SIX: BANB) informed the public… more |
12. Dec 2019
Change on the Bachem Corporate Executive CommitteeBubendorf/Basel, Switzerland, December 12, 2019 – Bachem (SIX: BANB) announced today that Dr. Thomas… more |
23. Aug 2019
Half-Year Report 2019: Record sales of 134.5 million CHF and surge in operating income in the first halfSignificant sales and EBIT growth EBITDA at 27.1% and EBIT at 18.2% of sales Capital increase… more |
08. May 2019
Results of the capital increaseOnly available in the German version Please click here more |
23. Apr 2019
Key figures for capital increase as announcedOnly available in the german version Please click here more |
10. Apr 2019
Annual General Meeting approves all Board proposalsOnly available in the german version Please click here more |
08. Mar 2019
2018 fiscal year: Record sales and increased operating incomeContinued growth and record sales of 282.5 million CHFIncrease in EBIT margin to 19.4% and… more |
08. Mar 2019
Bachem plans capital increaseOnly available on the german version Please click here more |
26. Oct 2018
Thomas Meier to become new COO of Bachem GroupBubendorf/Basel, Switzerland, October 26, 2018 – Bachem (SIX: BANB) announced today that Thomas… more |
24. Aug 2018
First half of 2018: Further rise in net profit; delayed sales/EBIT to be made good in second halfNet income 14.9% of sales EBITDA at 26.0% and EBIT at 16.2% of sales Delayed sales and EBIT… more |
20. Jul 2018
Bachem: Footprint in AsiaBubendorf/Basel, July 20, 2018 – Bachem (SIX: BANB) announced today the establishment of a new… more |
04. May 2018
Bachem site in St Helens, UK, obtains ISO certificationBubendorf/Basel, May 4, 2018 – Bachem (SIX: BANB) announced today that the UK site has been… more |
16. Mar 2018
Fiscal year 2017: Continued increase in sales, profitability and earningsContinued growth and new record sales of 261.6 million CHFEBIT margin rises to 19.3% while EBITDA… more |
01. Sep 2017
Dr. Anne-Kathrin Stoller to assume CMO position at BachemBubendorf/Basel, September 1, 2017 – Bachem (SIX: BANB) announced today that Dr. Anne-Kathrin… more |
25. Aug 2017
First half of 2017: New record sales and a solid operating resultSales and EBIT further increasedEBITDA at 26.6% and EBIT at 17.9% of salesNet profit affected by… more |
17. Mar 2017
Fiscal year 2016: Another year of strong sales and profit growthMomentum intact and new sales record setEBIT margin climbs to 19.1%, EBITDA margin to… more |
24. Feb 2017
Bachem expands its Corporate Executive CommitteeBubendorf/Basel, February 24, 2017 – Bachem (SIX: BANB) announced today that Dr. Alex Fässler has… more |
07. Feb 2017
Bachem renews supply contract with AstraZenecaBubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its… more |
04. Oct 2016
Bachem – Reinforced Collaboration with DOTTIKON ES on Novel Amino AcidsBubendorf/Basel, Switzerland, October 4, 2016 – Bachem Group (SIX: BANB) and DOTTIKON ES announce… more |
26. Aug 2016
First half of 2016: New sales record and sharp jump in profitsNew sales record with 13.9% year-on-year growth EBITDA at 26.2% and EBIT at 18.3% of salesNet income… more |
11. Mar 2016
Fiscal year 2015: Record sales and creation of new jobs· Sales grow 13.8% in local currency and pass the 200 million CHF thresholdEBIT margin of 18.5% and… more |
07. Sep 2015
Bachem and ILS extend their collaboration in Japan by an Exclusive Agency AgreementBubendorf/Basel, Switzerland and Ibaraki, Japan, September 7th, 2015 – Bachem (SIX: BANB) and ILS… more |
28. Aug 2015
First half 2015: Record sales and solid profit growthBubendorf/Basel, August 28, 2015 – Bachem Group (SIX: BANB) increased its sales by about 15% to… more |
17. Apr 2015
Bachem engages Professor Stephen B.H. Kent as Scientific Advisor and enters collaboration with the University of ChicagoBubendorf/Basel, April 17, 2015 - Bachem (SIX: BANB) is pleased to announce today that it has… more |
20. Mar 2015
Fiscal year 2014: Renewed sales growth and sharply higher profitsBubendorf/Basel, March 20, 2015 – Bachem Group (SIX: BANB), the technology leader in the field of… more |
27. Feb 2015
Bachem acquires American Peptide CompanyBubendorf/Basel, February 27, 2015 – Bachem (SIX: BANB), the leading peptide manufacturer, announced… more |
06. Oct 2014
Bachem AG and GlyTech, Inc. announce co-promotion agreementBubendorf/Basel, October 7, 2014 - Bachem the leading peptide manufacturer, and GlyTech Inc. (Kyoto,… more |
29. Aug 2014
First half 2014: Strong sales and profit growth / guidance confirmedBubendorf/Basel, August 29, 2014 – Bachem Group (SIX: BANB) significantly improved its performance… more |
25. Aug 2014
Dr. Guenther Loidl to assume CTO position at Bachem GroupBubendorf/Basel, August 25, 2014 – Bachem (SIX: BANB) announced today that Dr. Günther Loidl will… more |
21. Mar 2014
Fiscal Year 2013: Sales beat overall market growth, profits sharply higherBachem Group (SIX: BANB), the market leader in the field of peptide chemistry with a distinctive… more |
28. Nov 2013
Prof. Dr. Helma Wennemers nominated for election to Board of Directors and early cancellation of the temporary increase in weekly working hoursBubendorf/Basel, November 28, 2013 – At its latest meeting the Board of Directors of Bachem Holding… more |
23. Aug 2013
Half-Year Report 2013: Confirmation of upward trendBubendorf/Basel, August 23, 2013 – Bachem Group (SIX: BANB) continued to grow in the first half of… more |
10. Jul 2013
Pioneering breakthrough in the chemical synthesis of Interferon β-1aBubendorf/Basel, Switzerland and Kyoto, Japan July 10, 2013 - GlyTech, Inc. (Kyoto, Japan) and… more |
25. Apr 2013
Bachem switching from IFRS to Swiss GAAP FERBubendorf/Basel, April 25, 2013 – The Board of Directors of Bachem Holding AG (SIX: BANB) passed a… more |
15. Mar 2013
2012 financial year: Bachem clearly tops prior-year results at all levelsBachem Group (SIX: BANB) generated sales of 157.3 million CHF in the 2012 financial year in the face… more |
24. Aug 2012
Bachem well on track in a challenging marketBachem Group (SIX: BANB) reported sales of 76.2 million CHF for the first half of 2012. Sales were… more |
16. Mar 2012
Bachem confirms upward trend in its anniversary year - positive developments in terms of local sales, productivity and cost managementBachem Group (SIX: BANB) recorded sales of 145.8 million CHF in the challenging 2011 financial year… more |
07. Mar 2012
Dr. José de Chastonay appointed Chief Marketing Officer of the Bachem GroupBachem (SIX: BANB) announced today that Dr. José de Chastonay will succeed Dr. Lester Mills as Chief… more |
02. Mar 2012
Bachem and BioSpring agree to collaborate on oligonucleotide-peptide conjugates for R&DBachem (SIX: BANB) and BioSpring GmbH today announced that the two companies have concluded an… more |
09. Dec 2011
Bachem expects local sales growth of 6% to 8% in 2011Today the Bachem Group reduced its expected sales growth rate for the 2011 financial year, from its… more |
04. Nov 2011
Bachem increases working hours at Swiss sitesBachem Group (SIX: BANB) today announced that it will increase the work time at its operating sites… more |
02. Nov 2011
Change in Bachem's Corporate Executive CommitteeBachem Group (SIX: BANB) today announced a change in senior management. Dr. Lester Mills, Chief… more |
02. Sep 2011
Passing of the Baton at Bachem GroupBachem Group (SIX: BANB) today announced top-level management changes that will take effect in April… more |
26. Aug 2011
Bachem Shows Strength and Continues the UpswingBachem Group <media 1410 _top>(SIX: BANB)</media> performed well during the first semester of 2011… more |
09. Aug 2011
Bachem renews supply contract with AstraZenecaBachem today announced the renewal of a supply agreement with AstraZeneca, thereby extending the… more |
29. Jun 2011
Bachem celebrates 40th anniversaryBachem AG, market leader in peptide-based active pharmaceutical ingredients for the pharma and… more |
10. Jun 2011
Integration of Sochinaz SA completed at mid-yearThe plant in Vionnaz will operate as a branch of Bachem AG with the same line of products and… more |
11. Mar 2011
Bachem regains the upswing - significantly improved Business Performance in second semesterThe Bachem Group gained significant momentum in the second half of 2010 after a slow start to the… more |
09. Sep 2010
Bachem and Atheris collaborate on Melusine® venom peptide libraries for lead discoveryBachem today announced that the company concluded an agreement with Atheris Laboratories to market… more |
20. Aug 2010
Difficult start to first half-year of 2010 for the Bachem GroupPositive sales trend thanks to acquisition of projects and recovery of demand. In the first half of… more |
17. Jun 2010
Bachem sells stake in Polyphor to Ingro Finanz AGBachem today announced that the company on June 16, 2010, has sold its complete stake in Polyphor AG… more |
02. Jun 2010
Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP for phase III clinical trialsBachem and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the… more |
19. Mar 2010
Bachem confirms high profitability also in the business year 2009Bachem today confirms high profitability also in the business year 2009, although North America… more |
19. Mar 2010
Bachem confirms high profitability also in the business year 2009Bachem today confirms high profitability also in the business year 2009, although North America… more |
14. Aug 2009
Bachem Group Half-Year Results 2009Compared with the first half of 2008, overall sales are down 7.6% in CHF. The EBIT margin is at… more |
26. May 2009
Stephan Schindler to become new CFO of Bachem GroupBachem today announced that Stephan Schindler will succeed Michael Hüsler as CFO of the Bachem Group… more |
23. Apr 2009
Annual General Meeting elects new member of the Board of DirectorsBachem announced today that Dr. Jürgen Brokatzky-Geiger was elected at the Annual General Meeting of… more |
31. Mar 2009
Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin PamoateBachem and Debiopharm today announced the conclusion of a follow-up agreement for the long-term… more |
13. Mar 2009
Bachem announces financial results for the business year 2008In the business year 2008, the Bachem Group achieved sales of CHF 195.0 million. Compared with the… more |
28. Jan 2009
Bionor Immuno and Bachem sign agreement on supply of active ingredients and finished dosage forms for Bionor Immuno's vaccine development projectsBachem and Bionor Immuno announced today the conclusion of an agreement for the development and… more |
17. Sep 2008
Bachem enlarges Corporate Executive CommitteeBachem announced today that Dr. Lester Mills will become the fourth member of the company's… more |
15. Aug 2008
Bachem Group Half-Year Result 2008Sales of the Bachem Group reached CHF 98.7 million in the first six months of 2008. In local… more |
10. Apr 2008
Action Pharma and Bachem cooperate on AP214 - now ready to enter Phase 2 clinical trialsAction Pharma A/S and Bachem today announced their cooperation on AP214, Action Pharma's lead… more |
14. Mar 2008
Record year for Bachem at all levels in 2007Sales grow to CHF 198.3 Million - up 17.0% in local currencies and 15.5% in CHF… more |
04. Feb 2008
Bachem production facilities licensed for the manufacture of APIs for the Japanese marketBachem announced today that the Japanese Ministry of Health, Labour and Welfare has granted the… more |
17. Aug 2007
New record results for Bachem in the first half of 2007With an increase in sales of 25.4% in CHF or 26.3% in local currencies compared with the first six… more |
09. Aug 2007
Bachem Joint Venture Pevion Biotech Secures CHF 35 Million in Series A Financing RoundBachem today announced that the company has participated in the first substantial private financing… more |
20. Jun 2007
Bachem renews supply agreement with AstraZenecaBachem today announced the renewal of a supply agreement with AstraZeneca. Bachem has supplied… more |
30. May 2007
Bachem and Intercell agree long-term supply contract for peptide component of vaccine adjuvant IC31Bachem and Intercell AG today announced the conclusion of a long-term supply agreement for KLK. In… more |
09. May 2007
Neuren and Bachem continue close collaboration on Glypromate® - Neuren's lead product now in phase IIIBachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on… more |
16. Mar 2007
Bachem reports record results on 2006 sales and profitThe Bachem Group (SWX: BANB) today announced results for the business year 2006. The company… more |
11. Jan 2007
Bachem and Ardana Sign Long-term Supply Agreement for AviptadilBachem AG and Ardana plc today announced the conclusion of a long-term supply agreement for… more |
18. Aug 2006
Bachem posts sharp rise in profits in the first half of 2006- Sales growth of 16.3% in CHF and 14.4% in local currencies - Operating profit and net profit up… more |
27. Jul 2006
Bachem Completes Expansion of Peptide Manufacturing Capacities in the USThe Bachem Group (SWX: BANB) announced today that it has opened its new production unit at its US… more |
07. Apr 2006
Bachem reports record year: highest turnover in the company's history and marked net income growth- Record sales driven by strong second half and continued dynamic growth of the active ingredients… more |
29. Mar 2006
Bachem Group with new production unit for cytotoxic substancesThe Bachem Group announced today that, at the end of 2005, its subsidiary Sochinaz SA completed the… more |
16. Mar 2006
Bachem and Debio conclude long-term supply agreement for triptorelin pamoateBachem and Debio conclude long-term supply agreement for triptorelin pamoate. Bachem AG today… more |
09. Mar 2006
Swedish Orphan International and Bachem conclude long-term supply agreement for nitisinoneBachem AG, Bubendorf, Switzerland and Swedish Orphan International AB, Stockholm, Sweden, today… more |
27. Jan 2006
Bachem 2005 - Strong second half drives record sales.The Bachem Group (SWX: BANB) recorded its highest sales ever in 2005, totaling CHF 153.7 million.… more |